HerediGENE is a test that fully analyzes a panel of genes, including BRCA1 and BRCA2, which are associated with increased risk of developing breast, ovarian and other hereditary cancers.
PrIME is a cancer molecular test that incorporates a 500+ tumor-related multi-gene panel associated with targeted therapies. Furthermore, it includes four major biomarkers (PD-L1, MSI, TMB and LOH) related to immunotherapy response.
Mo.Re. (Molecular Response) is a multi-gene assay developed to provide an insight to the tumor’s biology of each patient.
Personalized pharmacotherapy based on human DNA.
are a series of clinically verified, highly sensitive and specific multi-gene tests that analyze the genes associated with inherited cardiovascular disease.
are a series of clinically verified, highly sensitive and specific multi-gene tests that analyze genes associated with hereditary neurological and developmental disorders.
Tumor Mutational Burden (TMB) is an emerging, independent predictive biomarker of immunotherapies in multiple tumor types, including lung cancer.
Microsatellite Instability (MSI) is a condition that appears on the DNA of specific cells (such as cancer cells) where the number of microsatellites (short repeats of DNA sequences) in these cells, is different from the repeats that existed in the DNA when it was inherited.
The PD-L1 test helps doctors determine whether a patient is likely to benefit from cancer drugs known as immune checkpoint inhibitors.
PCA3 is a non-invasive test for the detection of prostate cancer, highly specific and more precise than all other available screening tests for prostate cancer and is performed on a simple urine sample.
In Genekor, we offer Single Gene analysis with the highest quality, using the most advanced technology available.
The iGenome gene test analyzes more than 20,000 genes associated with inherited diseases, helping the doctor diagnose diseases with unclear phenotypes and antenatal care.
Genekor is a Molecular Biology Laboratory, focused in Oncology, Cardiology, Neurology and Pharmacogenetics. Our journey began in 2007 and we constantly grow in order to provide the highest quality services in the Molecular Medicine sector. A passionate team sharing the same vision on quality healthcare and molecular science is working together in order to provide patients and physicians with reliable actionable information.
Genekor’s highly experienced scientific and management team are cooperating passionately in order to provide the physicians and patients with the highest quality services in Oncology, Cardiology, Neurology and Pharmacogenetics.
See Genekor' s publications and posters.
Article in "The Doctor" magazine by members of the scientific research team of hereditary cancer of Genekor Medical.They write: Konstantinos Agiannitopoulos Molecular Biologist, MSc, PhD & Despina Apostolopoulou Molecular Biologist, MSc, PhD
NGS PLATFORM - ITS CONTRIBUTION TO CLINICAL PRACTICE
In recent years, Next Generation Sequencing (NGS) technology
has been actively introduced into clinical practice,
playing an essential role in understanding
the genetics of many diseases, such as cancer.
NGS platforms include 3 main categories: 1) targeted gene panels,
2) sequencing of all exons, ie the regions of the genome encoding proteins
(Whole Exome Sequencing-WES) and 3) sequencing of
the entire genome (Whole W Genome Sequencing) ).
With the use of NGS it is possible to detect both mutations
in genes associated with hereditary cancer and the analysis of
the molecular profile of the tumor (somatic mutations).
For more information visit:
https://www.genekor.com/en/about-genekor/
30.08.2021